Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
China's NRDL to be Implemented Next Yr; BEONE MEDICINES Has 2 Drugs Shortlisted
Recommend 6 Positive 3 Negative 1 |
||||
|
||||
|
The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2025)", along with the first edition of the "Commercial Health Insurance Innovative Drug List (2025)". The new drug list will be officially implemented from January 1, 2026. The National Reimbursement Drug List (NRDL) successfully added 114 new drugs, with 50 being innovative drugs, achieving an overall success rate of 88%, evidently higher than the 76% in 2024. In the commercial health insurance innovative drug list, 19 drugs from 18 innovative pharmaceutical companies were shortlisted, with BEONE MEDICINES (06160.HK) being the only company with two drugs listed. Among them, five CAR-T cell drugs for cancer treatment were included, developed by Fosun Kairos, JW THERAP-B (02126.HK), and other pharmaceutical companies, with pricing close to or exceeding RMB1 million. Additionally, drugs from Eli Lilly (LLY.US), Eisai, Pfizer, Johnson & Johnson (JNJ.US), and Bristol Bristol-Myers Squibb (BMY.US) were also listed. BEONE MEDICINES last priced at HKD194.8, down 1.62%, with a trading volume of 1.4342 million shares, involving HKD279 million. JW THERAP-B (02126.HK) last priced at HKD3.29, up 6.82%, with a trading volume of 1.97 million shares, involving HKD6.4975 million. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
